Ganitumab is a human monoclonal antibody against type 1 insulin-like growth factor receptor ( IGF1R), designed for the treatment of cancers. Ganitumab was developed by

Amgen Amgen Inc. (formerly Applied Molecular Genetics Inc.) is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. One of the world's largest independent biotechnology companies, Amgen was established in T ...

. A phase III clinical trial (for metastatic pancreatic cancer) was abandoned in August 2012.

References

Amgen Abandoned drugs {{antineoplastic-drug-stub